UBS Group
FENC icon

UBS Group’s Fennec Pharmaceuticals FENC Stock Holding History

UBS Group’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$39.8K Buy
6,472
+1,477
+30% +$11.4K ﹤0.01% 7523
2025
Q4 		$38.5K Sell
4,995
-8,715
-64% -$71.5K ﹤0.01% 7362
2025
Q3 		$128K Buy
13,710
+686
+5% +$5.94K ﹤0.01% 6953
2025
Q2 		$108K Sell
13,024
-13,230
-50% -$90.5K ﹤0.01% 7176
2025
Q1 		$160K Buy
26,254
+10,732
+69% +$68.9K ﹤0.01% 6704
2024
Q4 		$98.1K Buy
15,522
+4,299
+38% +$22K ﹤0.01% 6889
2024
Q3 		$56.1K Buy
11,223
+3,955
+54% +$22.9K ﹤0.01% 6741
2024
Q2 		$44.4K Sell
7,268
-22,350
-75% -$186K ﹤0.01% 6781
2024
Q1 		$329K Buy
29,618
+9,649
+48% +$96.9K ﹤0.01% 5507
2023
Q4 		$224K Buy
19,969
+9,979
+100% +$82.7K ﹤0.01% 5718
2023
Q3 		$75K Sell
9,990
-542
-5% -$4.41K ﹤0.01% 6029
2023
Q2 		$93K Buy
10,532
+9,827
+1,394% +$81.7K ﹤0.01% 6070
2023
Q1 		$5.87K Buy
705
+641
+1,002% +$5.95K ﹤0.01% 7978
2022
Q4 		$614 Sell
64
-3,035
-98% -$26.9K ﹤0.01% 10119
2022
Q3 		$26K Buy
3,099
+3,035
+4,742% +$20.8K ﹤0.01% 7045
2022
Q2 		$0 Sell
64
-1,032
-94% -$5.99K ﹤0.01% 10493
2022
Q1 		$6K Sell
1,096
-6,681
-86% -$33.7K ﹤0.01% 8964
2021
Q4 		$34K Buy
7,777
+7,713
+12,052% +$57.4K ﹤0.01% 7260
2021
Q3 		$1K Sell
64
-58,922
-100% -$442K ﹤0.01% 9178
2021
Q2 		$430K Buy
58,986
+18,417
+45% +$123K ﹤0.01% 4844
2021
Q1 		$252K Buy
40,569
+37,019
+1,043% +$279K ﹤0.01% 5321
2020
Q4 		$26K Buy
+3,550
New +$27K ﹤0.01% 6747
2020
Q3 		– Sell
-6,887
Closed -$58K – 8113
2020
Q2 		$58K Buy
+6,887
New +$51.2K ﹤0.01% 5736
2020
Q1 		– Sell
-983
Closed -$6K – 8077
2019
Q4 		$6K Sell
983
-1,319
-57% -$7.09K ﹤0.01% 7509
2019
Q3 		$11K Buy
2,302
+2,195
+2,051% +$9.69K ﹤0.01% 7098
2019
Q2 		$0 Sell
107
-204
-66% -$864 ﹤0.01% 7954
2019
Q1 		$2K Sell
311
-6,884
-96% -$45.3K ﹤0.01% 7435
2018
Q4 		$46K Buy
7,195
+4,396
+157% +$30.7K ﹤0.01% 6161
2018
Q3 		$23K Sell
2,799
-1,494
-35% -$13.9K ﹤0.01% 6721
2018
Q2 		$45K Buy
+4,293
New +$50.9K ﹤0.01% 6059
2018
Q1 		– Sell
-813
Closed -$8K – 7920
2017
Q4 		$8K Buy
813
+734
+929% +$7.33K ﹤0.01% 7149
2017
Q3 		$1K Buy
+79
New +$917 ﹤0.01% 7566

Other funds holding FENC

RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCM
Potomac Capital Management New York $115M AUM

UBS Group's FENC Position: Q1 2026 in Review

UBS Group increased its Fennec Pharmaceuticals (FENC) stake by 30% in Q1 2026, buying an estimated $11.4K and bringing the position to 6,472 shares worth $39.8K. The position accounts for ﹤0.01% of the portfolio, ranked #7523.

UBS Group first reported a position in FENC in Q3 2017 and has held it in 32 quarters since. The position peaked at $430K in Q2 2021. 90 funds tracked by Wall St. Rank hold FENC as of Q1 2026.

  • UBS Group held 6,472 shares of Fennec Pharmaceuticals worth $39.8K as of Q1 2026.
  • UBS Group bought 1,477 Fennec Pharmaceuticals shares in Q1 2026, an estimated $11.4K.
  • Fennec Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #7523 holding.
  • UBS Group first reported a position in Fennec Pharmaceuticals in Q3 2017 and has held it in 32 quarters since.
  • UBS Group's Fennec Pharmaceuticals position peaked at $430K in Q2 2021.
  • 90 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.